BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update

Rhea-AI Summary

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced a conference call on March 30, 2023, at 8:00 a.m. ET to discuss financial results for the fourth quarter and full year ended December 31, 2022, along with corporate updates. The call will feature leaders including President Chaim Lebovits and Co-CEO Stacy Lindborg, PhD. Shareholders are invited to submit questions by March 26, 2023. Call details include toll-free and international participant numbers, with a webcast available at this link. BrainStorm develops therapies for neurodegenerative diseases, notably for ALS using its proprietary NurOwn® technology.

Positive

• Upcoming conference call to discuss Q4 and FY 2022 financial results, enhancing transparency with investors.
• Leaders presenting may boost confidence in operational expertise and future direction.

Negative

• No concrete financial performance metrics or guidance provided ahead of the conference call, potentially causing uncertainty.

NEW YORK, March 21, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Thursday, March 30^th.

 

BrainStorm's President and Chief Executive Officer, Chaim Lebovits, and Co-Chief Executive Officer, Stacy Lindborg, PhD will present a corporate update after which investment community questions will be answered.  Joining Mr. Lebovits and Dr. Lindborg in the Q&A session will be David Setboun, PharmD, MBA, Executive Vice President and Chief Operating Officer, and Alla Patlis, CPA, MBA, Interim Chief Financial Officer.

Participants are encouraged to submit their questions in advance of the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. Eastern Time on Sunday, March 26, 2023.

The investment community may participate in the conference call by dialing the following numbers:

Participant Numbers:
Toll Free:         877 545 0523                             
International:   973 528 0016 
Entry Code:     943129                     

Webcast URL: https://bit.ly/40EuACf 

Participants will be greeted by an operator and asked for the access code. If a caller does not have the code, they can reference the company name. We have found that using access codes expedites entry into the call and suggest the code be distributed with the dial in numbers.

Those interested in listening to the conference call live via the internet may do so by using the webcast link above or by visiting the "Investors & Media" page of BrainStorm's website at

https://ir.brainstorm-cell.com/events-and-presentations and clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

Teleconference Replay Number:             

Toll Free:                877 481 4010
International:          919 882 2331
Replay Passcode:  47908

Teleconference Replay Expiration: Thursday, April 13, 2023

About BrainStorm Cell Therapeutics Inc. 

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive MS and was supported by a grant from the National MS Society (NMSS).

Safe-Harbor Statement 

Statements in this announcement other than historical data and information, including statements regarding BrainStorm's Type A meeting with the FDA and the clinical development of NurOwn® as a therapy for the treatment of ALS, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "intend," "should," "could," "will," "believe," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn®, whether BrainStorm's future interactions with the FDA will have productive outcomes, the impacts of the COVID-19 pandemic on our clinical trials, supply chain, and operations, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

For more information, visit the company's website at www.brainstorm-cell.com.

Contacts:

 Investor Relations:
John Mullaly
LifeSci Advisors, LLC
Phone: +1 617-429-3548
jmullaly@lifesciadvisors.com 

Media: 
Lisa Guiterman
Phone: +1 202-330-3431
lisa.guiterman@gmail.com  

Logo:  https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/brainstorm-to-announce-fourth-quarter-and-fiscal-year-2022-financial-results-and-provide-a-corporate-update-301777321.html

SOURCE BrainStorm Cell Therapeutics Inc.

FAQ

When will BrainStorm Cell Therapeutics announce its financial results for 2022?

BrainStorm Cell Therapeutics will announce its financial results on March 30, 2023.

What is the significance of the March 30 conference call for BCLI investors?

The conference call will provide critical updates on financial results and corporate strategy, which are important for BCLI investors.

How can I participate in the BrainStorm conference call?

You can participate by dialing the toll-free or international numbers provided or by joining the webcast at the specified URL.

Who will present during the BrainStorm Q4 financial results call?

The call will feature CEO Chaim Lebovits, Co-CEO Stacy Lindborg, and other executives.

What technology does BrainStorm use for treating ALS?

BrainStorm uses its proprietary NurOwn® technology for developing treatments for ALS.